Geopolitical risk has resurfaced, but the nearterm impact on European listed real estate remains contained. Rising energydriven inflation and rates are driving greater dispersion and sharpening the focus on balancesheet quality, while MIPIM 2026 highlighted a pragmatic investor approach. In this report, we adjust target prices and refresh our top picks, removing CTP and adding Irish Residential REIT. Geopolitics and energy: duration matters more than headlines
Orange: Orange Board of Directors appoints Frédéric Sanchez as Chairman Press releaseParis, 20 March 2026 Orange Board of Directors appoints Frédéric Sanchez as Chairman The Board of Directors of Orange has decided to appoint Frédéric Sanchez, an independent director of Orange since 2020 and Chair of the Strategy and Technology Committee, as Chairman of the Board of Directors of Orange at the close of the Annual Shareholders’ Meeting to be held on 19 May 2026. This decision is based on the recommendations of the Governance, Corporate Social and Environmental Responsibility Committee (CG...
Orange : Frédéric Sanchez nommé président du conseil d’administration d’Orange Communiqué de presseParis, le 20 mars 2026 Frédéric Sanchez nommé président du conseil d’administration d’Orange Le conseil d’administration d’Orange a décidé de nommer Frédéric Sanchez, administrateur indépendant d’Orange depuis 2020 et président du Comité stratégie et technologie, président du conseil d’administration d’Orange à l’issue de l’assemblée générale des actionnaires du 19 mai 2026. Cette décision s’appuie sur les recommandations du comité de gouvernance, de responsabilité sociale et environnement...
A director at Deutsche Lufthansa AG bought 10,000 shares at 7.520EUR and the significance rating of the trade was 58/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...
Berichtigung der Veröffentlichung vom 20. Mar 2026/ 09:15 CET/CEST - Deutsche Lufthansa AG: Herr Carsten Spohr, Kauf Berichtigung der Veröffentlichung vom 20. Mar 2026/ 09:15 CET/CEST - Deutsche Lufthansa AG: Herr Carsten Spohr, Kauf Korrektur einer Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen,20. Mar 2026 / 12:22 CET/CEST, übermittelt von GlobeNewswire. Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. 1. Angaben zu den Personen, die Führungsau...
Correction of the publication from 20. Mar 2026/ 09:15 CET/CEST - Deutsche Lufthansa AG: Mr Carsten Spohr, Acquisition Correction of the publication from 20. Mar 2026/ 09:15 CET/CEST - Deutsche Lufthansa AG: Mr Carsten Spohr, Acquisition Correction of a Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them,20. Mar 2026 / 12:22 CET/CEST, transmitted by GlobeNewswire. The issuer is solely responsible for the content of this announcement. 1. Details of the person discharging managerial resp...
Deutsche Lufthansa AG: Herr Carsten Spohr, Kauf Deutsche Lufthansa AG: Herr Carsten Spohr, Kauf Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen,20. Mar 2026 / 09:15 CET/CEST, übermittelt von GlobeNewswire. Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. 1. Angaben zu den Personen, die Führungsaufgaben wahrnehmen, sowie zu den in enger Beziehung zu ihnen stehenden Personen a) Name Titel Herr ...
Deutsche Lufthansa AG: Mr Carsten Spohr, Acquisition Deutsche Lufthansa AG: Mr Carsten Spohr, Acquisition Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them,20. Mar 2026 / 09:15 CET/CEST, transmitted by GlobeNewswire. The issuer is solely responsible for the content of this announcement. 1. Details of the person discharging managerial responsibilities / person closely associated a) Name Title Mr First n...
With the glyphosate litigation nearing a decision, we think investors will refocus on Bayer's fundamentals. Improved prospects in the Pharma division and multiple tailwinds in CropScience in 2027 will provide further impetus. Additionally, as litigation risks fade and the DSO programme progresses, the spin-off of Consumer Health could be back on the table. All this fundamentally alters our assessment of Bayer, and we are upgrading the stock to Outperform, with a new TP of € 55.
Orange: Transactions carried out as part of a share buyback program and outside of a liquidity contract Press releaseParis, 16 March 2026 Transactions carried out as part of a share buyback program and outside of a liquidity contract Orange announces that it has purchased treasury shares within the framework of its share buyback program These shares have been acquired to honor obligations related to long-term incentive plans for corporate officers and senior employees. The long-term incentive plans, which are conditional on presence and performance, were set up with the aim of involving ...
Orange : Information sur les opérations effectuées dans le cadre d’un programme de rachat d’actions, hors contrat de liquidité Communiqué de presseParis, le 16 mars 2026 Information sur les opérations effectuées dans le cadre d’un programme de rachat d’actions, hors contrat de liquidité Orange annonce avoir procédé à l'acquisition d'actions propres dans le cadre de son programme de rachat d'actions. Cette acquisition est destinée à honorer des obligations liées aux plans conditionnés de rémunération variable pluriannuelle des dirigeants mandataires sociaux et des cadres dirigeants (long ...
Grifols Shares Results From its Chronos Platform Identifying Early Molecular Changes Associated with Parkinson’s Disease Chronos‑PD shows that biological changes associated with Parkinson’s disease (PD) can emerge up to 12 years before clinical diagnosisUncovered reproducible early molecular signals and distinct molecular patterns in PD, supporting future efforts in patient stratification and precision medicine researchChronos is part of a broad Grifols program to find early disease biomarkers leveraging more than 100 million proprietary plasma samples connected to real-world data on thousa...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.